MXPA03011244A - Nuevos derivados de indol con afinidad por el receptor 5-ht6. - Google Patents
Nuevos derivados de indol con afinidad por el receptor 5-ht6.Info
- Publication number
- MXPA03011244A MXPA03011244A MXPA03011244A MXPA03011244A MXPA03011244A MX PA03011244 A MXPA03011244 A MX PA03011244A MX PA03011244 A MXPA03011244 A MX PA03011244A MX PA03011244 A MXPA03011244 A MX PA03011244A MX PA03011244 A MXPA03011244 A MX PA03011244A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor affinity
- indole derivatives
- new indole
- compounds
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta invencion se refiere a compuestos que tienen generalmente afinidad por el receptor 5-HT6 y que son representados por la Formula I (ver formula): en donde uno de R5, R6 o R7 es un grupo de formula genera! B, en donde w es un grupo -CH- o un atomo de nitrogeno, y los otros sustituyentes son tal como se definen aqui; o isomeros individuales, mezclas racemicas o no racemicas de isomeros, o sales o solvatos farmaceuticamente aceptables de los mismos. La invencion ademas se refiere a composiciones farmaceuticas que contienen tales compuestos, su uso como agentes terapeuticos, y los metodos de preparacion de las mismas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29670501P | 2001-06-07 | 2001-06-07 | |
US34021201P | 2001-12-13 | 2001-12-13 | |
PCT/EP2002/005890 WO2002098857A1 (en) | 2001-06-07 | 2002-05-29 | New indole derivatives with 5-ht6 receptor affinity |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03011244A true MXPA03011244A (es) | 2004-02-27 |
Family
ID=26969776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03011244A MXPA03011244A (es) | 2001-06-07 | 2002-05-29 | Nuevos derivados de indol con afinidad por el receptor 5-ht6. |
Country Status (33)
Country | Link |
---|---|
US (3) | US6787535B2 (es) |
EP (1) | EP1401813B1 (es) |
JP (1) | JP4187642B2 (es) |
KR (1) | KR100600240B1 (es) |
CN (1) | CN1257892C (es) |
AR (1) | AR036233A1 (es) |
AT (1) | ATE353318T1 (es) |
AU (1) | AU2002310747B2 (es) |
BG (1) | BG108420A (es) |
BR (1) | BR0210929A (es) |
CA (1) | CA2449874C (es) |
CO (1) | CO5630036A2 (es) |
CZ (1) | CZ20033529A3 (es) |
DE (1) | DE60218037T2 (es) |
ES (1) | ES2280546T3 (es) |
HK (1) | HK1068610A1 (es) |
HR (1) | HRP20030984A2 (es) |
HU (1) | HUP0401307A2 (es) |
IL (1) | IL158997A0 (es) |
MA (1) | MA27032A1 (es) |
MX (1) | MXPA03011244A (es) |
NO (1) | NO20035359D0 (es) |
NZ (1) | NZ529631A (es) |
PA (1) | PA8546601A1 (es) |
PE (1) | PE20030039A1 (es) |
PL (1) | PL367305A1 (es) |
RU (1) | RU2294932C2 (es) |
SK (1) | SK16052003A3 (es) |
TW (1) | TW591015B (es) |
UY (1) | UY27322A1 (es) |
WO (1) | WO2002098857A1 (es) |
YU (1) | YU96103A (es) |
ZA (1) | ZA200309005B (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU98003A (sh) | 2001-06-11 | 2006-03-03 | Biovitrum Ab. | Supstituisana sulfonamidna jedinjenja, postupak za njihovu upotrebu kao leka za tretiranje poremećaja cns, gojaznosti i dijabetesa tipa ii |
JP2005527463A (ja) * | 2001-08-07 | 2005-09-15 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Cns疾患を治療するための5−ht6受容体アフィニティーを有する3−アリールスルホニル−7−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン |
ES2307919T3 (es) | 2002-03-27 | 2008-12-01 | Glaxo Group Limited | Derivados de quinolina y su uso como ligandos de 5-ht6. |
UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
TW200400177A (en) * | 2002-06-04 | 2004-01-01 | Wyeth Corp | 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands |
EP1897876A3 (en) * | 2002-06-20 | 2009-03-18 | Biovitrum AB (publ) | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
US7943639B2 (en) | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
EA008835B1 (ru) * | 2002-06-20 | 2007-08-31 | Биовитрум Аб | Замещенные сульфоны и сульфонамиды и фармацевтические композиции на их основе, применимые для лечения ожирения, сахарного диабета ii типа и расстройств центральной нервной системы |
DE60313895T2 (de) | 2002-09-17 | 2008-01-17 | F. Hoffmann-La Roche Ag | 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren |
BRPI0407493A (pt) | 2003-02-14 | 2006-02-14 | Wyeth Corp | derivados heterociclil-3-sulfinilazaindol ou -azaindazol como ligantes de 5-hidroxitriptamina-6 |
PT1626720E (pt) | 2003-04-04 | 2008-11-10 | Lundbeck & Co As H | Derivados de 4-(2-fenilsulfanil-fenil)-piperidina como inibidores da recaptação da serotonina |
DK1558582T3 (da) | 2003-07-22 | 2006-05-08 | Arena Pharm Inc | Diaryl og arylheteroarylureaderivater som modulatorer af aktiviteten af 5-HT2A-serotoninreceptoren anvendelige til profylakse eller behandling af forstyrrelser relateret dertil |
SE0303480D0 (sv) * | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
CA2545506A1 (en) * | 2003-12-19 | 2005-06-30 | Biovitrum Ab | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder |
EP1694323A4 (en) * | 2003-12-19 | 2009-05-13 | Elixir Pharmaceuticals Inc | METHOD FOR TREATING A DISEASE |
PL1701940T3 (pl) | 2003-12-23 | 2008-11-28 | H Lundbeck As | Pochodne 2-(1H-indolilosulfanylo)benzyloaminy jako SSRI |
GB0400895D0 (en) * | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
TW200616967A (en) * | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
AR052308A1 (es) * | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
ES2359725T3 (es) * | 2004-09-30 | 2011-05-26 | F. Hoffmann-La Roche Ag | Composiciones y métodos para el tratamiento de trastornos cognitivos. |
WO2006062481A1 (en) * | 2004-12-09 | 2006-06-15 | Biovitrum Ab | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
US7629473B2 (en) | 2005-06-17 | 2009-12-08 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-aryl amine derivatives |
AR054393A1 (es) | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos. |
US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
CN101282938A (zh) * | 2005-08-15 | 2008-10-08 | 惠氏公司 | 作为5-羟色胺-6配体的经取代3-磺酰基吲唑衍生物 |
ES2274725B1 (es) * | 2005-11-08 | 2008-04-01 | Laboratorios Del Dr. Esteve, S.A. | Indeno derivados, su preparacion y su uso como medicamentos. |
CA2636007A1 (en) * | 2006-01-13 | 2007-07-26 | Wyeth | Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors |
JP2010519171A (ja) * | 2006-02-17 | 2010-06-03 | メモリー・ファーマシューティカルズ・コーポレイション | 5−ht6受容体親和性を有する化合物 |
JP2010509259A (ja) | 2006-11-09 | 2010-03-25 | エフ.ホフマン−ラ ロシュ アーゲー | インドール及びベンゾフラン2−カルボキサミド誘導体 |
KR101176894B1 (ko) * | 2007-01-08 | 2012-08-30 | 수벤 라이프 사이언시스 리미티드 | 4?(헤테로시클릴)알킬?n?(아릴술포닐) 인돌 화합물 및 이들의 5?ht6 리간드로서 용도 |
MX2009006077A (es) | 2007-01-08 | 2009-06-17 | Suven Life Sciences Ltd | Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6. |
US20080200471A1 (en) * | 2007-02-16 | 2008-08-21 | Memory Pharmaceuticals Corporation | 6' substituted compounds having 5-ht6 receptor affinity |
JP2010521516A (ja) * | 2007-03-21 | 2010-06-24 | グラクソ グループ リミテッド | 疼痛および過敏性腸症候群の治療におけるキノリン誘導体の使用 |
PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
CA2683124C (en) | 2007-05-03 | 2012-09-25 | Suven Life Sciences Limited | Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands |
EP2162433A2 (en) * | 2007-05-24 | 2010-03-17 | Memory Pharmaceuticals Corporation | 4' substituted compounds having 5-ht6 receptor affinity |
CN101801194A (zh) * | 2007-08-15 | 2010-08-11 | 记忆医药公司 | 具有5-ht6受体亲和力的3’取代的化合物 |
ATE518833T1 (de) | 2007-10-26 | 2011-08-15 | Suven Life Sciences Ltd | Aminoarylsulfonamidverbindungen und ihre verwendung als 5-ht6-liganden |
WO2009074607A1 (en) | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
AU2009214190A1 (en) * | 2008-02-15 | 2009-08-20 | F. Hoffmann-La Roche Ag | 3-alkyl-piperazine derivatives and uses thereof |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US20100016297A1 (en) * | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
US20100022581A1 (en) * | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
US20100029629A1 (en) * | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
US20100056531A1 (en) * | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
KR101308819B1 (ko) | 2008-09-17 | 2013-09-13 | 수벤 라이프 사이언시스 리미티드 | 아릴 술폰아미드 아민 화합물 및 5-ht6 리간드로서의 용도 |
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
EP2406249A1 (en) | 2009-03-10 | 2012-01-18 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
MX2012007783A (es) | 2010-01-05 | 2012-10-03 | Suven Life Sciences Ltd | Compuestos sulfona que actuan como ligandos del receptor 5-ht6. |
ES2646834T3 (es) | 2010-08-20 | 2017-12-18 | Amira Pharmaceuticals, Inc. | Inhibidores de autotaxina y usos de los mismos |
WO2012166415A1 (en) | 2011-05-27 | 2012-12-06 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
CN102924359B (zh) * | 2012-10-30 | 2015-03-11 | 中国科学院烟台海岸带研究所 | 一种一锅法合成取代吲哚类化合物的方法 |
JP6454346B2 (ja) | 2013-12-20 | 2019-01-16 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 芳香族複素環式化合物及び医薬におけるその応用 |
AU2015286049B2 (en) | 2014-07-08 | 2018-03-01 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
MX2017016413A (es) | 2015-06-12 | 2018-08-01 | Axovant Sciences Gmbh | Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem. |
RU2018103338A (ru) | 2015-07-15 | 2019-08-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0773942A1 (en) * | 1994-07-26 | 1997-05-21 | Pfizer Inc. | 4-indole derivatives as serotonin agonists and antagonists |
GB9517559D0 (en) * | 1995-08-26 | 1995-10-25 | Smithkline Beecham Plc | Novel compounds |
DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
EP0975593A1 (en) * | 1997-04-18 | 2000-02-02 | Smithkline Beecham Plc | Indole derivatives having combined 5ht1a, 5ht1b and 5ht1d receptor antagonist activity |
US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
EP1173432B9 (en) * | 1999-04-21 | 2008-10-15 | NPS Allelix Corp. | Piperidine-indole compounds having 5-ht6 affinity |
AU1542201A (en) * | 1999-11-05 | 2001-05-14 | Nps Allelix Corp. | Compounds having 5-HT6 receptor antagonist activity |
BR0115102B1 (pt) * | 2000-11-02 | 2013-11-26 | Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos | |
US7034029B2 (en) * | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
DK1355900T3 (da) * | 2000-12-22 | 2006-09-11 | Wyeth Corp | Heterocyclylalkylindol- eller -azaindolforbindelser som 5-hydroxytryptamin-6-ligander |
KR20030062442A (ko) * | 2000-12-22 | 2003-07-25 | 와이어쓰 | 5-하이드록시트립타민-6-리간드로서의 헤테로사이클인다졸및 아자인다졸 화합물 |
TW593278B (en) * | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
PL367297A1 (en) * | 2001-04-20 | 2005-02-21 | Wyeth | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
JP2005527463A (ja) * | 2001-08-07 | 2005-09-15 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Cns疾患を治療するための5−ht6受容体アフィニティーを有する3−アリールスルホニル−7−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン |
JP2006505559A (ja) * | 2002-10-18 | 2006-02-16 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht6受容体親和性を持つ4−ピペラジニルベンゼンスルホニルインドール |
-
2002
- 2002-05-29 CZ CZ20033529A patent/CZ20033529A3/cs unknown
- 2002-05-29 AU AU2002310747A patent/AU2002310747B2/en not_active Ceased
- 2002-05-29 ES ES02735394T patent/ES2280546T3/es not_active Expired - Lifetime
- 2002-05-29 DE DE60218037T patent/DE60218037T2/de not_active Expired - Lifetime
- 2002-05-29 CN CNB028115244A patent/CN1257892C/zh not_active Expired - Fee Related
- 2002-05-29 PL PL02367305A patent/PL367305A1/xx not_active Application Discontinuation
- 2002-05-29 WO PCT/EP2002/005890 patent/WO2002098857A1/en active IP Right Grant
- 2002-05-29 SK SK16052003A patent/SK16052003A3/sk unknown
- 2002-05-29 EP EP02735394A patent/EP1401813B1/en not_active Expired - Lifetime
- 2002-05-29 YU YU96103A patent/YU96103A/sh unknown
- 2002-05-29 JP JP2003501846A patent/JP4187642B2/ja not_active Expired - Fee Related
- 2002-05-29 BR BR0210929-8A patent/BR0210929A/pt not_active Application Discontinuation
- 2002-05-29 AT AT02735394T patent/ATE353318T1/de not_active IP Right Cessation
- 2002-05-29 RU RU2003136731/04A patent/RU2294932C2/ru not_active IP Right Cessation
- 2002-05-29 IL IL15899702A patent/IL158997A0/xx unknown
- 2002-05-29 HU HU0401307A patent/HUP0401307A2/hu unknown
- 2002-05-29 MX MXPA03011244A patent/MXPA03011244A/es active IP Right Grant
- 2002-05-29 KR KR1020037016022A patent/KR100600240B1/ko not_active IP Right Cessation
- 2002-05-29 CA CA002449874A patent/CA2449874C/en not_active Expired - Fee Related
- 2002-05-29 NZ NZ529631A patent/NZ529631A/en unknown
- 2002-06-03 TW TW091111843A patent/TW591015B/zh not_active IP Right Cessation
- 2002-06-04 PA PA20028546601A patent/PA8546601A1/es unknown
- 2002-06-04 AR ARP020102066A patent/AR036233A1/es not_active Application Discontinuation
- 2002-06-06 US US10/164,660 patent/US6787535B2/en not_active Expired - Fee Related
- 2002-06-06 UY UY27322A patent/UY27322A1/es not_active Application Discontinuation
- 2002-06-07 PE PE2002000481A patent/PE20030039A1/es not_active Application Discontinuation
-
2003
- 2003-11-19 ZA ZA200309005A patent/ZA200309005B/en unknown
- 2003-11-26 HR HR20030984A patent/HRP20030984A2/hr not_active Application Discontinuation
- 2003-12-02 CO CO03106073A patent/CO5630036A2/es not_active Application Discontinuation
- 2003-12-02 NO NO20035359A patent/NO20035359D0/no not_active Application Discontinuation
- 2003-12-03 MA MA27422A patent/MA27032A1/fr unknown
- 2003-12-05 BG BG108420A patent/BG108420A/xx unknown
-
2004
- 2004-06-25 US US10/876,863 patent/US20040248902A1/en not_active Abandoned
-
2005
- 2005-01-27 HK HK05100706A patent/HK1068610A1/xx not_active IP Right Cessation
- 2005-03-03 US US11/071,726 patent/US20050171118A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03011244A (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6. | |
MXPA03011638A (es) | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. | |
MXPA04007414A (es) | Indoles sustituidos como agonistas alfa-1. | |
PA8550201A1 (es) | Analogos de prostaglandina | |
HK1070054A1 (en) | Arylsulfonyl derivatives with5-ht6 receptor affinity | |
NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
ID23954A (id) | Tetrahidrogama-karbolin | |
MXPA04005426A (es) | Derivados de pirazol de anillos fuisionados. | |
MXPA04005313A (es) | Derivados de aminotetralin como antagonistas del receptor muscarinico. | |
MXPA04006113A (es) | Derivados de triazoloquinolina utiles como ligandos receptores de adenosina. | |
MXPA04006115A (es) | Derivados de imidazoquinolina. | |
DE602004016177D1 (de) | Methylindole und methylpyrrolopyridine als alpha-1-adrenerge agonisten | |
SE0301371D0 (sv) | New Compounds | |
ECSP034870A (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |